![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
As of October 2023, Amedeo had |
Inflammatory Bowel Diseases |
Free Subscription
1 Aliment Pharmacol Ther |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Inflammatory Bowel Diseases is free of charge.
Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It
depends on how you use the drug. Authors' reply.
Aliment Pharmacol Ther. 2023 Nov 4. doi: 10.1111/apt.17796.
PubMed
Healthcare service use in paediatric inflammatory bowel disease: a questionnaire
on patient and parent care experiences in Germany.
BMC Gastroenterol. 2023;23:378.
PubMed
Abstract available
Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients
with Inflammatory Bowel Disease: A Comparison to ELISA.
Dig Dis Sci. 2023 Nov 9. doi: 10.1007/s10620-023-08139.
PubMed
Abstract available
Standardizing Endoscopic Reporting in Patients with IBD: JEDII to the Rescue?
Dig Dis Sci. 2023;68:4287-4289.
PubMed
The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy
a Tolerable Alternative or a Perpetual Annoyance?
Dig Dis Sci. 2023;68:4279-4281.
PubMed
Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin
lymphoma.
Eur J Gastroenterol Hepatol. 2023;35:1349-1353.
PubMed
Abstract available
Post-colonoscopy rectal cancer in Swedish patients with Crohn's disease
2001-2015: a population-based case review study.
Eur J Gastroenterol Hepatol. 2023;35:1334-1340.
PubMed
Abstract available
The value of whole-body dual-energy x-ray absorptiometry in assessing body
composition in patients with inflammatory bowel disease: a prospective study.
Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002675.
PubMed
Abstract available
Could gut and food-derived yeast be responsible for activating T-cells in Crohn
disease?
Gastroenterology. 2023 Nov 3:S0016-5085(23)05204.
PubMed
Mirikizumab for the Management of Ulcerative Colitis.
Gastroenterology. 2023 Nov 3:S0016-5085(23)05206.
PubMed
Evaluating lleal Pouch Anal Anastomosis Function: Time to Expand Our
ARM-amentarium.
Inflamm Bowel Dis. 2023;29:1819-1825.
PubMed
Abstract available
Histologic Predictors of Clinical Outcomes and Healthcare Utilization in Patients
With Ileal Pouch-Anal Anastomosis.
Inflamm Bowel Dis. 2023;29:1769-1777.
PubMed
Abstract available
Impact of Opioid Use on the Natural History of Inflammatory Bowel Disease:
Prospective Longitudinal Follow-up Study.
Inflamm Bowel Dis. 2023 Oct 31:izad256. doi: 10.1093.
PubMed
Abstract available
Rates of Endoscopic Recurrence In Postoperative Crohn's Disease Based on
Anastomotic Techniques: A Systematic Review And Meta-Analysis.
Inflamm Bowel Dis. 2023 Nov 1:izad252. doi: 10.1093.
PubMed
Abstract available
Crohn's Disease Mortality and Ambient Air Pollution in New York City.
Inflamm Bowel Dis. 2023 Nov 2:izad243. doi: 10.1093.
PubMed
Abstract available
An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis
of Online Public Forum Posts.
Inflamm Bowel Dis. 2023 Nov 2:izad247. doi: 10.1093.
PubMed
Abstract available
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory
Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.
Inflamm Bowel Dis. 2023 Nov 2:izad258. doi: 10.1093.
PubMed
Abstract available
Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform
Infection in Inflammatory Bowel Disease Patients.
Inflamm Bowel Dis. 2023 Nov 3:izad265. doi: 10.1093.
PubMed
A Systematic Review on the Increasing Incidence of Inflammatory Bowel Disease in
Southeast Asia: Looking Beyond the Urbanization Phenomenon.
Inflamm Bowel Dis. 2023 Nov 3:izad189. doi: 10.1093.
PubMed
Abstract available
De-escalation of biological treatment in inflammatory bowel disease: A
comprehensive review.
J Crohns Colitis. 2023 Nov 1:jjad181. doi: 10.1093.
PubMed
Abstract available
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib
in Patients with Ulcerative Colitis: a Post Hoc Analysis of the Phase 3 Clinical
Trial Programme.
J Crohns Colitis. 2023 Nov 6:jjad190. doi: 10.1093.
PubMed
Abstract available
Antibody responses to Influenza vaccination are diminished in patients with
inflammatory bowel disease on infliximab or tofacitinib.
J Crohns Colitis. 2023 Nov 6:jjad182. doi: 10.1093.
PubMed
Abstract available
Early versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic,
and Histological Outcomes.
J Crohns Colitis. 2023 Nov 2:jjad179. doi: 10.1093.
PubMed
Abstract available
Higher serum infliximab concentrations following subcutaneous dosing are
associated with deep remission in patients with inflammatory bowel disease.
J Crohns Colitis. 2023 Nov 2:jjad188. doi: 10.1093.
PubMed
Abstract available
Pharmacological therapies for the management of fistulising Crohn's disease: A
systematic review and meta-analysis.
J Crohns Colitis. 2023 Nov 2:jjad185. doi: 10.1093.
PubMed
Abstract available
Initial management of intraabdominal abscesses and preventive strategies for
abscess recurrence in penetrating Crohn's disease: a national multicenter study
based on ENEIDA registry.
J Crohns Colitis. 2023 Nov 1:jjad184. doi: 10.1093.
PubMed
Abstract available
Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory
bowel disease.
PLoS One. 2023;18:e0288147.
PubMed
Abstract available
Colonic mucosal associated invariant T cells in Crohn's disease have a diverse
and non-public T cell receptor beta chain repertoire.
PLoS One. 2023;18:e0285918.
PubMed
Abstract available
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results
from a spanish open-label cohort.
Scand J Gastroenterol. 2023 Nov 6:1-9. doi: 10.1080/00365521.2023.2278427.
PubMed
Abstract available
[Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory
Bowel Disease Working Group of the Austrian Society of Gastroenterology and
Hepatology (OGGH)].
Z Gastroenterol. 2023;61:1518-1525.
PubMed
Abstract available
Thank you for your interest in scientific medicine.